annb0t
Top 20
Kineta, Inc.
SEATTLE, June 28, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today the appointment of Kim Drapkin and Scott Dylla, Ph.D. to its Board of Directors. Ms. Drapkin will join the companyâs audit and compensation committees and Dr. Dylla will join the compensation committee.
âKim and Scottâs extensive strategi...
>>> Read more: Kineta Expands Board of Directors with Biotech Industry Leaders Kim Drapkin and Scott Dylla
SEATTLE, June 28, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today the appointment of Kim Drapkin and Scott Dylla, Ph.D. to its Board of Directors. Ms. Drapkin will join the companyâs audit and compensation committees and Dr. Dylla will join the compensation committee.
âKim and Scottâs extensive strategi...
>>> Read more: Kineta Expands Board of Directors with Biotech Industry Leaders Kim Drapkin and Scott Dylla
